Search
Terconazole
go.drugbank.com/drugs/DB00251Approved[A178096] Terconazole was initially approved by the FDA in 1987.
Products: Terazol 3 Vaginal Ovules 80mgVerteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet
Oxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respir...
Mixtures: ASE-COLD 120 mg+50mg+1mg/5 ml PEDİATRİK ŞURUPProducts: PEREBRON 50MG/5 ML 120 ML SURUPEthylmorphine
go.drugbank.com/drugs/DB01466IllicitInvestigationalIt is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world.
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigational[A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[L2879] By Health Canada, the balsam of Peru is approved by the use of over-the-counter combination products and it is currently approved in veterinary products. … It is constituted by a mixture of substances from which the major components are benzyl cinnamate and [DB00676].
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawn[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.[L1118] It was never approved by the FDA.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnBoceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigationalIn May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL. … [A259736,A258488,A259761,L46516] Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant